Researchers at Piper Jaffray Reiterated their “Hold” rating for Depomed (DEPO). The Price Target is Set to $9.0; Capital Advisors Has Lowered Its Johnson & Johnson (JNJ) Holding

December 7, 2017 - By test

Among 14 analysts covering Depomed Inc (NASDAQ:DEPO), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Depomed Inc has $33 highest and $6.0 lowest target. $15.25’s average target is 88.04% above currents $8.11 stock price. Depomed Inc had 48 analyst reports since July 30, 2015 according to SRatingsIntel. The company was maintained on Friday, October 13 by Piper Jaffray. The rating was downgraded by TheStreet on Friday, October 16 to “Hold”. The stock has “Hold” rating by Cantor Fitzgerald on Tuesday, November 8. The stock has “Outperform” rating by Northland Capital on Thursday, March 24. The stock has “Buy” rating by Mizuho on Wednesday, November 9. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, July 30. The company was initiated on Monday, February 8 by Piper Jaffray. Roth Capital maintained it with “Buy” rating and $24 target in Wednesday, November 11 report. The rating was maintained by RBC Capital Markets on Thursday, September 14 with “Hold”. RBC Capital Markets maintained Depomed, Inc. (NASDAQ:DEPO) rating on Wednesday, November 8. RBC Capital Markets has “Hold” rating and $6.0 target.

Capital Advisors Inc decreased Johnson & Johnson (JNJ) stake by 41.19% reported in 2017Q2 SEC filing. Capital Advisors Inc sold 60,195 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The Capital Advisors Inc holds 85,959 shares with $11.37 million value, down from 146,154 last quarter. Johnson & Johnson now has $378.96B valuation. The stock increased 1.00% or $1.39 during the last trading session, reaching $141.06. About 5.59M shares traded or 4.28% up from the average. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since December 7, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 13 have Buy rating, 5 Sell and 5 Hold. Therefore 57% are positive. Johnson & Johnson had 83 analyst reports since August 7, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of JNJ in report on Friday, October 6 with “Buy” rating. The stock of Johnson & Johnson (NYSE:JNJ) earned “Neutral” rating by Goldman Sachs on Monday, March 14. The rating was maintained by BMO Capital Markets on Thursday, October 5 with “Buy”. The firm has “Hold” rating given on Tuesday, July 18 by Piper Jaffray. Goldman Sachs downgraded the stock to “Sell” rating in Wednesday, September 20 report. UBS maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, July 19. UBS has “Buy” rating and $14800 target. The firm has “Overweight” rating given on Wednesday, April 20 by Barclays Capital. The stock of Johnson & Johnson (NYSE:JNJ) has “Hold” rating given on Wednesday, April 6 by Societe Generale. Stifel Nicolaus maintained it with “Hold” rating and $14000 target in Tuesday, July 18 report. As per Thursday, August 24, the company rating was maintained by Cowen & Co.

Investors sentiment decreased to 0.83 in 2017 Q2. Its down 0.03, from 0.86 in 2017Q1. It dived, as 50 investors sold JNJ shares while 878 reduced holdings. 105 funds opened positions while 667 raised stakes. 1.73 billion shares or 0.03% less from 1.73 billion shares in 2017Q1 were reported. Natl Service Wi holds 3.2% or 23,023 shares in its portfolio. Mengis Cap Management owns 29,645 shares for 2.78% of their portfolio. Stadion Money Mngmt Limited Liability reported 14,553 shares. Highvista Strategies Lc reported 4,200 shares. New England Private Wealth Limited Liability Company has 5,566 shares for 0.23% of their portfolio. Halsey Associates Ct invested 1.6% of its portfolio in Johnson & Johnson (NYSE:JNJ). Frontier Inv holds 2.7% or 208,854 shares in its portfolio. Moreover, Sheets Smith Wealth Mngmt has 0.5% invested in Johnson & Johnson (NYSE:JNJ). Loeb Partners Corp has 1.77% invested in Johnson & Johnson (NYSE:JNJ) for 46,700 shares. Truepoint Inc accumulated 0.03% or 2,289 shares. Department Mb Bankshares N A owns 129,927 shares. Johnson Invest Counsel stated it has 0.85% of its portfolio in Johnson & Johnson (NYSE:JNJ). Woodmont Inv Counsel reported 41,385 shares. Salient Cap Advsr Limited Liability Corp reported 0.22% of its portfolio in Johnson & Johnson (NYSE:JNJ). Capital Advsr Ltd Liability Com invested 1.31% of its portfolio in Johnson & Johnson (NYSE:JNJ).

Capital Advisors Inc increased Ishares Tr stake by 43,474 shares to 2.89M valued at $72.82M in 2017Q2. It also upped Pbf Energy Inc (NYSE:PBF) stake by 18,538 shares and now owns 492,490 shares. Vanguard Whitehall Fds Inc was raised too.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 23. They expect $1.72 EPS, up 8.86% or $0.14 from last year’s $1.58 per share. JNJ’s profit will be $4.62 billion for 20.50 P/E if the $1.72 EPS becomes a reality. After $1.90 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -9.47% negative EPS growth.

The stock increased 3.18% or $0.25 during the last trading session, reaching $8.11. About 2.49M shares traded or 56.66% up from the average. Depomed, Inc. (NASDAQ:DEPO) has declined 46.86% since December 7, 2016 and is downtrending. It has underperformed by 63.56% the S&P500.

Analysts await Depomed, Inc. (NASDAQ:DEPO) to report earnings on February, 20. They expect $-0.22 earnings per share, up 69.44% or $0.50 from last year’s $-0.72 per share. After $-0.25 actual earnings per share reported by Depomed, Inc. for the previous quarter, Wall Street now forecasts -12.00% EPS growth.

Investors sentiment decreased to 0.87 in 2017 Q2. Its down 0.29, from 1.16 in 2017Q1. It fall, as 33 investors sold Depomed, Inc. shares while 54 reduced holdings. 31 funds opened positions while 45 raised stakes. 54.71 million shares or 0.42% less from 54.94 million shares in 2017Q1 were reported. Invesco reported 220,142 shares or 0% of all its holdings. Ameriprise, a Minnesota-based fund reported 333,508 shares. 1492 Ltd Llc holds 0.13% in Depomed, Inc. (NASDAQ:DEPO) or 13,550 shares. Fifth Third National Bank owns 156 shares or 0% of their US portfolio. Da Davidson Com holds 2,432 shares. Bogle Mngmt Ltd Partnership De has invested 0.78% in Depomed, Inc. (NASDAQ:DEPO). Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% stake. Nationwide Fund Advsr owns 35,938 shares for 0% of their portfolio. Citadel Advsr Limited Liability Com invested in 0% or 14,704 shares. Commercial Bank Of America Corporation De has invested 0% in Depomed, Inc. (NASDAQ:DEPO). Quantitative Invest Ltd Liability Com has 31,200 shares. Ls Inv Llc, Michigan-based fund reported 2,353 shares. Meeder Asset Mgmt has 768 shares. One Trading L P holds 0% or 30,242 shares. Wells Fargo And Com Mn stated it has 0% in Depomed, Inc. (NASDAQ:DEPO).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.